Prodotti competitors / Area Oncology 17 gennaio 2025 FDA approves datopotamab deruxtecan for unresectable or metastatic, HR-positive, HER2-negative breast cancer
Prodotti competitors / Area Oncology 24 settembre 2024 Datopotamab deruxtecan: final overall survival results reported in patients with metastatic HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial
Prodotti competitors / Area Oncology 23 settembre 2024 Survival results for datopotamab deruxtecan in TROPION- Breast01 did not achieve statistical significance versus chemotherapy
Prodotti competitors / Area Oncology 23 settembre 2024 Datopotamab deruxtecan final overall survival results in patients with metastatic HR-positive, HER2-low or negative breast cancer did not achieve statistical significance versus chemotherapy
Prodotti competitors / Area Oncology 5 marzo 2024 Avvio in EMA dell'iter registrativo per datopotamab deruxtecan nel cancro del polmone non squamoso localmente avanzato o metastatico e nel cancro al seno HR positivo/HER2 negativo
Prodotti competitors / Area Oncology 22 settembre 2023 Datopotamab deruxtecan Phase 3 study TROPION-Breast01 positive results for PFS in HR+/HER2- Breast Cancer
